1 Introduction to Research & Analysis Reports
1.1 Non-Tyrosine Kinase Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Tyrosine Kinase Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Tyrosine Kinase Inhibitors Overall Market Size
2.1 Global Non-Tyrosine Kinase Inhibitors Market Size: 2022 VS 2029
2.2 Global Non-Tyrosine Kinase Inhibitors Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Non-Tyrosine Kinase Inhibitors Sales: 2018-2029
3 Company Landscape
3.1 Top Non-Tyrosine Kinase Inhibitors Players in Global Market
3.2 Top Global Non-Tyrosine Kinase Inhibitors Companies Ranked by Revenue
3.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Companies
3.4 Global Non-Tyrosine Kinase Inhibitors Sales by Companies
3.5 Global Non-Tyrosine Kinase Inhibitors Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Non-Tyrosine Kinase Inhibitors Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Non-Tyrosine Kinase Inhibitors Product Type
3.8 Tier 1, Tier 2 and Tier 3 Non-Tyrosine Kinase Inhibitors Players in Global Market
3.8.1 List of Global Tier 1 Non-Tyrosine Kinase Inhibitors Companies
3.8.2 List of Global Tier 2 and Tier 3 Non-Tyrosine Kinase Inhibitors Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Non-Tyrosine Kinase Inhibitors Market Size Markets, 2022 & 2029
4.1.2 mTOR Inhibitors
4.1.3 RAF/MEK Inhibitors
4.1.4 CDK Inhibitors
4.2 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
4.2.1 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
4.2.2 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
4.2.3 By Type – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
4.3 By Type – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
4.3.1 By Type – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
4.3.2 By Type – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
4.3.3 By Type – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
4.4 By Type – Global Non-Tyrosine Kinase Inhibitors Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Non-Tyrosine Kinase Inhibitors Market Size, 2022 & 2029
5.1.2 Liver Cancer
5.1.3 Respiratory Cancer
5.1.4 Brain Cancer
5.1.5 Others
5.2 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
5.2.1 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
5.2.2 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
5.2.3 By Application – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
5.3 By Application – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
5.3.1 By Application – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
5.3.2 By Application – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
5.3.3 By Application – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
5.4 By Application – Global Non-Tyrosine Kinase Inhibitors Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Non-Tyrosine Kinase Inhibitors Market Size, 2022 & 2029
6.2 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue & Forecasts
6.2.1 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue, 2018-2023
6.2.2 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue, 2024-2029
6.2.3 By Region – Global Non-Tyrosine Kinase Inhibitors Revenue Market Share, 2018-2029
6.3 By Region – Global Non-Tyrosine Kinase Inhibitors Sales & Forecasts
6.3.1 By Region – Global Non-Tyrosine Kinase Inhibitors Sales, 2018-2023
6.3.2 By Region – Global Non-Tyrosine Kinase Inhibitors Sales, 2024-2029
6.3.3 By Region – Global Non-Tyrosine Kinase Inhibitors Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.4.2 By Country – North America Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.4.3 US Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.4.4 Canada Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.4.5 Mexico Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.5.2 By Country – Europe Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.5.3 Germany Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.4 France Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.5 U.K. Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.6 Italy Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.7 Russia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.8 Nordic Countries Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.5.9 Benelux Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.6.2 By Region – Asia Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.6.3 China Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.4 Japan Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.5 South Korea Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.6 Southeast Asia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.6.7 India Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.7.2 By Country – South America Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.7.3 Brazil Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.7.4 Argentina Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales, 2018-2029
6.8.3 Turkey Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.4 Israel Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.5 Saudi Arabia Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
6.8.6 UAE Non-Tyrosine Kinase Inhibitors Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.1.4 Roche Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.2.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.3.4 Novartis Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Array BioPharma
7.4.1 Array BioPharma Company Summary
7.4.2 Array BioPharma Business Overview
7.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.4.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.4.5 Array BioPharma Key News & Latest Developments
7.5 Nerviano Medical Sciences
7.5.1 Nerviano Medical Sciences Company Summary
7.5.2 Nerviano Medical Sciences Business Overview
7.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.5.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.5.5 Nerviano Medical Sciences Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.6.4 Pfizer Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Merck KGaA
7.7.1 Merck KGaA Company Summary
7.7.2 Merck KGaA Business Overview
7.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.7.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.7.5 Merck KGaA Key News & Latest Developments
7.8 Astex Pharmaceuticals
7.8.1 Astex Pharmaceuticals Company Summary
7.8.2 Astex Pharmaceuticals Business Overview
7.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.8.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.8.5 Astex Pharmaceuticals Key News & Latest Developments
7.9 Cyclacel Pharmaceuticals
7.9.1 Cyclacel Pharmaceuticals Company Summary
7.9.2 Cyclacel Pharmaceuticals Business Overview
7.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.9.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.9.5 Cyclacel Pharmaceuticals Key News & Latest Developments
7.10 Daiichi Sankyo
7.10.1 Daiichi Sankyo Company Summary
7.10.2 Daiichi Sankyo Business Overview
7.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.10.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.10.5 Daiichi Sankyo Key News & Latest Developments
7.11 Onconova Therapeutics
7.11.1 Onconova Therapeutics Company Summary
7.11.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Business Overview
7.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.11.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.11.5 Onconova Therapeutics Key News & Latest Developments
7.12 AstraZeneca
7.12.1 AstraZeneca Company Summary
7.12.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Business Overview
7.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.12.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.12.5 AstraZeneca Key News & Latest Developments
7.13 GlaxoSmithKline (GSK)
7.13.1 GlaxoSmithKline (GSK) Company Summary
7.13.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Business Overview
7.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.13.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.13.5 GlaxoSmithKline (GSK) Key News & Latest Developments
7.14 Carna Biosciences
7.14.1 Carna Biosciences Company Summary
7.14.2 Carna Biosciences Business Overview
7.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.14.5 Carna Biosciences Key News & Latest Developments
7.15 Celgene Corporation
7.15.1 Celgene Corporation Company Summary
7.15.2 Celgene Corporation Business Overview
7.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.15.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.15.5 Celgene Corporation Key News & Latest Developments
7.16 Eternity Bioscience
7.16.1 Eternity Bioscience Company Summary
7.16.2 Eternity Bioscience Business Overview
7.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.16.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.16.5 Eternity Bioscience Key News & Latest Developments
7.17 Jasco Pharmaceuticals
7.17.1 Jasco Pharmaceuticals Company Summary
7.17.2 Jasco Pharmaceuticals Business Overview
7.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Major Product Offerings
7.17.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales and Revenue in Global (2018-2023)
7.17.5 Jasco Pharmaceuticals Key News & Latest Developments
8 Global Non-Tyrosine Kinase Inhibitors Production Capacity, Analysis
8.1 Global Non-Tyrosine Kinase Inhibitors Production Capacity, 2018-2029
8.2 Non-Tyrosine Kinase Inhibitors Production Capacity of Key Manufacturers in Global Market
8.3 Global Non-Tyrosine Kinase Inhibitors Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Non-Tyrosine Kinase Inhibitors Supply Chain Analysis
10.1 Non-Tyrosine Kinase Inhibitors Industry Value Chain
10.2 Non-Tyrosine Kinase Inhibitors Upstream Market
10.3 Non-Tyrosine Kinase Inhibitors Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Non-Tyrosine Kinase Inhibitors Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界の非チロシンキナーゼ阻害剤市場予測2023-2029：mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤 |
| 【英語タイトル】Non-Tyrosine Kinase Inhibitors Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5814 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：110 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の非チロシンキナーゼ阻害剤市場規模と予測を収録しています。・世界の非チロシンキナーゼ阻害剤市場：売上、2018年-2023年、2024年-2029年 ・世界の非チロシンキナーゼ阻害剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の非チロシンキナーゼ阻害剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「mTOR阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 非チロシンキナーゼ阻害剤のグローバル主要企業は、Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、非チロシンキナーゼ阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の非チロシンキナーゼ阻害剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の非チロシンキナーゼ阻害剤市場：タイプ別市場シェア、2022年 ・mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤 世界の非チロシンキナーゼ阻害剤市場：用途別、2018年-2023年、2024年-2029年 世界の非チロシンキナーゼ阻害剤市場：用途別市場シェア、2022年 ・肝臓がん、呼吸器がん、脳がん、その他 世界の非チロシンキナーゼ阻害剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の非チロシンキナーゼ阻害剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における非チロシンキナーゼ阻害剤のグローバル売上、2018年-2023年 ・主要企業における非チロシンキナーゼ阻害剤のグローバル売上シェア、2022年 ・主要企業における非チロシンキナーゼ阻害剤のグローバル販売量、2018年-2023年 ・主要企業における非チロシンキナーゼ阻害剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticals ************************************************************* ・調査・分析レポートの概要 非チロシンキナーゼ阻害剤市場の定義 市場セグメント 世界の非チロシンキナーゼ阻害剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の非チロシンキナーゼ阻害剤市場規模 世界の非チロシンキナーゼ阻害剤市場規模：2022年 VS 2029年 世界の非チロシンキナーゼ阻害剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの非チロシンキナーゼ阻害剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の非チロシンキナーゼ阻害剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤 非チロシンキナーゼ阻害剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：肝臓がん、呼吸器がん、脳がん、その他 非チロシンキナーゼ阻害剤の用途別グローバル売上・予測 ・地域別市場分析 地域別非チロシンキナーゼ阻害剤市場規模 2022年と2029年 地域別非チロシンキナーゼ阻害剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Roche、 Eli Lilly、 Novartis、 Array BioPharma、 Nerviano Medical Sciences、 Pfizer、 Merck KGaA、 Astex Pharmaceuticals、 Cyclacel Pharmaceuticals、 Daiichi Sankyo、 Onconova Therapeutics、 AstraZeneca、 GlaxoSmithKline (GSK)、 Carna Biosciences、 Celgene Corporation、 Eternity Bioscience、 Jasco Pharmaceuticals ... |
This report aims to provide a comprehensive presentation of the global market for Non-Tyrosine Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Tyrosine Kinase Inhibitors. This report contains market size and forecasts of Non-Tyrosine Kinase Inhibitors in global, including the following market information:
Global Non-Tyrosine Kinase Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Non-Tyrosine Kinase Inhibitors Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Non-Tyrosine Kinase Inhibitors companies in 2022 (%)
The global Non-Tyrosine Kinase Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
mTOR Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Tyrosine Kinase Inhibitors include Roche, Eli Lilly, Novartis, Array BioPharma, Nerviano Medical Sciences, Pfizer, Merck KGaA, Astex Pharmaceuticals and Cyclacel Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Tyrosine Kinase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Tyrosine Kinase Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, by Type, 2022 (%)
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Global Non-Tyrosine Kinase Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, by Application, 2022 (%)
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Global Non-Tyrosine Kinase Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Tyrosine Kinase Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Non-Tyrosine Kinase Inhibitors revenues share in global market, 2022 (%)
Key companies Non-Tyrosine Kinase Inhibitors sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Non-Tyrosine Kinase Inhibitors sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Tyrosine Kinase Inhibitors, market overview.
Chapter 2: Global Non-Tyrosine Kinase Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Tyrosine Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Non-Tyrosine Kinase Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の非チロシンキナーゼ阻害剤市場予測2023-2029：mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤] (コード：MMG23JU5814)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の非チロシンキナーゼ阻害剤市場予測2023-2029：mTOR阻害剤、RAF/MEK阻害剤、CDK阻害剤]についてメールでお問い合わせ |
